文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

早期脓毒症低血压中外周升压药的使用

Peripheral Vasopressor Use in Early Sepsis-Induced Hypotension.
PubMed 文献 · JAMA Netw Open · 2025-08-01
一句话结论在CLOVERS试验的前瞻性队列中,84.2%的早期脓毒症低血压患者经外周启动升压药,并发症罕见(0.6%),90天死亡率与中心启动无统计学差异。

该研究是CLOVERS试验的二次分析,纳入60家美国医院2018年3月至2022年2月收治的582例在入组24小时内使用升压药且入组时无中心静脉通路的脓毒症患者。主要分析升压药启动途径,次要分析外周升压药持续超过6小时的情况。结果显示,84.2%经外周启动,研究站点是唯一独立相关因素(中位OR 3.48;95%CI 1.57-5.38);外周启动与中心启动的90天死亡率无统计学差异(26.1% vs 37.0%;校正OR 0.67;95%CI 0.39-1.16);外周升压药并发症罕见且轻微(0.6%),无溃疡或组织损伤。作者认为这些发现支持早期脓毒症复苏中短期外周升压药使用的安全性和可行性。

要点

  • 在582例早期脓毒症低血压患者中,490例(84.2%)经外周静脉启动升压药,92例(15.8%)经中心静脉启动。
  • 研究站点是升压药启动途径的唯一独立相关因素(中位OR 3.48;95%CI 1.57-5.38)。
  • 校正分析中,外周 vs 中心启动的90天死亡率无统计学差异(26.1% vs 37.0%;校正OR 0.67;95%CI 0.39-1.16)。
  • 490例经外周启动者中333例(68.0%)外周升压药持续超过6小时。
  • 外周升压药并发症罕见且轻微(3/490,0.6%),无溃疡或组织损伤;而前72小时置入CVC的322例中12例(3.7%)发生14次CVC置入并发症。

适用人群与场景

  • CLOVERS试验中在入组24小时内接受升压药且入组时无中心静脉通路的脓毒症患者,来自60家美国医院,2018年3月至2022年2月。
  • 纳入患者中位(IQR)年龄63(52-72)岁,267例(45.9%)为女性,96例(16.5%)为非裔美国人,416例(71.5%)为白人,70例(12.0%)为其他种族或种族未报告。

研究设计与关键结果

  • 研究类型:前瞻性队列研究,CLOVERS试验的二次分析,纳入60家美国医院2018年3月至2022年2月的数据;共1563例CLOVERS患者中582例(37.2%)接受升压药并符合纳入标准。
  • 升压药启动途径:外周静脉导管490例(84.2%),中心静脉通路92例(15.8%);研究站点是唯一独立相关因素(中位OR 3.48;95%CI 1.57-5.38)。
  • 校正分析中,外周 vs 中心启动的90天死亡率无统计学差异(128例[26.1%] vs 34例[37.0%];校正OR 0.67;95%CI 0.39-1.16)。
  • 490例经外周启动者中333例(68.0%)外周升压药持续超过6小时。
  • 外周升压药并发症罕见且轻微(3/490,0.6%),无溃疡或组织损伤病例;前72小时置入CVC的322例中12例(3.7%)发生14次CVC置入并发症。

证据类型、等级与局限

  • 证据类型:前瞻性队列研究(CLOVERS试验的二次分析)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,这些发现支持早期脓毒症复苏中短期外周升压药使用的安全性和可行性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Evidence supporting the safety of infusing vasopressors through peripheral intravenous catheters (peripheral vasopressors) is largely derived from single-center studies, limiting generalizability.

OBJECTIVE: To evaluate factors associated with vasopressor route selection and assess safety and clinical outcomes of peripheral vasopressor administration in early sepsis resuscitation.

DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study is a secondary analysis of the Crystalloid Liberal vs Early Vasopressors in Sepsis (CLOVERS) trial conducted in 60 US hospitals from March 2018 to February 2022. Patients in CLOVERS who received vasopressors within 24 hours of enrollment and did not have central venous access at enrollment were included. Data were analyzed from January 2023 to June 2025.

EXPOSURE: Route of vasopressor initiation (central or peripheral).

MAIN OUTCOMES AND MEASURES: The primary analysis evaluated the route of vasopressor initiation, while the secondary analysis assessed continuation of peripheral vasopressors beyond 6 hours. Univariable and multivariable analyses of factors associated with vasopressor route were conducted, as was a multivariable analysis to evaluate the association of route with outcomes, including 90-day mortality. Descriptive statistics were used to summarize 28-day peripheral vasopressor and central venous catheter (CVC) complications.

RESULTS: Of 1563 patients in CLOVERS, 582 (37.2%) received vasopressors and met study inclusion criteria. Included patients had a median (IQR) age of 63 (52-72) years, and 267 (45.9%) were female, 96 (16.5%) were African American, 416 (71.5%) were White, and 70 (12.0%) were another race or had unreported race. Vasopressors were initiated via peripheral catheter in 490 patients (84.2%) and via central venous access in 92 patients (15.8%). Study site was the only factor independently associated with route of initiation (median odds ratio, 3.48; 95% CI, 1.57-5.38). In adjusted analyses, peripheral vs central initiation was associated with statistically comparable 90-day mortality (128 participants [26.1%] vs 34 participants [37.0%]; adjusted odds ratio, 0.67; 95% CI, 0.39-1.16). Peripheral vasopressors were continued beyond 6 hours in 333 of 490 patients (68.0%). Peripheral vasopressor complications were rare and low-grade (3 of 490 patients [0.6%]), with no cases of ulceration or tissue injury. In contrast, there were 14 complications from CVC placement occurring in 12 of 322 patients (3.7%) who had CVCs placed in the first 72 hours.

CONCLUSIONS AND RELEVANCE: In this prospective cohort study of the CLOVERS trial, peripheral administration of vasopressors was common and was associated with low complication rates. These findings support the safety and feasibility of short-term peripheral vasopressor use in early sepsis resuscitation.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Munroe ES, Co IN, Douglas I, et al. Peripheral Vasopressor Use in Early Sepsis-Induced Hypotension. JAMA Netw Open. 2025. PMID: 40864467. doi:10.1001/jamanetworkopen.2025.29148

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。